254 related articles for article (PubMed ID: 28992983)
1. Primary hyperparathyroidism.
Muñoz-Torres M; García-Martín A
Med Clin (Barc); 2018 Mar; 150(6):226-232. PubMed ID: 28992983
[TBL] [Abstract][Full Text] [Related]
2. [Normocalcemic primary hyperparathyroidism: a growing problem].
Martínez Díaz-Guerra G; Guadalix Iglesias S; Hawkins Carranza F
Med Clin (Barc); 2013 Aug; 141(3):125-9. PubMed ID: 23199831
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism.
Takeuchi Y; Takahashi S; Miura D; Katagiri M; Nakashima N; Ohishi H; Shimazaki R; Tominaga Y
J Bone Miner Metab; 2017 Nov; 35(6):616-622. PubMed ID: 27873072
[TBL] [Abstract][Full Text] [Related]
4. Primary Hyperparathyroidism: Effects on Bone Health.
Zanocco KA; Yeh MW
Endocrinol Metab Clin North Am; 2017 Mar; 46(1):87-104. PubMed ID: 28131138
[TBL] [Abstract][Full Text] [Related]
5. Persistent hypercalcemia after parathyroidectomy in an adolescent and effect of treatment with cinacalcet HCl.
Henrich LM; Rogol AD; D'Amour P; Levine MA; Hanks JB; Bruns DE
Clin Chem; 2006 Dec; 52(12):2286-93. PubMed ID: 17105782
[TBL] [Abstract][Full Text] [Related]
6. Further insights into the pathogenesis of primary hyperparathyroidism: a nested case-control study.
Rejnmark L; Amstrup AK; Mollerup CL; Heickendorff L; Mosekilde L
J Clin Endocrinol Metab; 2013 Jan; 98(1):87-96. PubMed ID: 23150677
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.
Peacock M; Bilezikian JP; Bolognese MA; Borofsky M; Scumpia S; Sterling LR; Cheng S; Shoback D
J Clin Endocrinol Metab; 2011 Jan; 96(1):E9-18. PubMed ID: 20943783
[TBL] [Abstract][Full Text] [Related]
8. [Low-dose cinacalcet reduces serum calcium in patients with primary hyperparathyroidism not eligible for surgery].
Arranz Martín A; Azcárate Villalón A; Luque Ramírez M; Santana Durán B; Marazuela Azpíroz M; Paniagua Ruiz A; Carraro R; Gómez Pan A
Endocrinol Nutr; 2011 Jan; 58(1):24-31. PubMed ID: 21277266
[TBL] [Abstract][Full Text] [Related]
9. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.
Del Prete M; Marotta V; Ramundo V; Marciello F; Di Sarno A; Esposito R; Carratù AC; De Luca Di Roseto C; Di Somma C; Colao A; Faggiano A
Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106
[TBL] [Abstract][Full Text] [Related]
10. Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.
Iglesias P; Ais G; González A; Tajada P; García Arévalo C; Fernández Pardo E; Díez JJ
Am J Med Sci; 2008 Feb; 335(2):111-4. PubMed ID: 18277118
[TBL] [Abstract][Full Text] [Related]
11. Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1).
Giusti F; Cianferotti L; Gronchi G; Cioppi F; Masi L; Faggiano A; Colao A; Ferolla P; Brandi ML
Endocrine; 2016 Jun; 52(3):495-506. PubMed ID: 26224587
[TBL] [Abstract][Full Text] [Related]
12. A novel use of cinacalcet to distinguish primary hyperparathyroidism from hypercalcemia of malignancy in a patient with a low-normal parathyroid hormone concentration.
Zwerling HK
Endocr Pract; 2012; 18(1):101-2. PubMed ID: 22336445
[No Abstract] [Full Text] [Related]
13. Sporadic and hereditary primary hyperparathyroidism.
Pepe J; Cipriani C; Pilotto R; De Lucia F; Castro C; Lenge L; Russo S; Guarnieri V; Scillitani A; Carnevale V; D'Erasmo E; Romagnoli E; Minisola S
J Endocrinol Invest; 2011 Jul; 34(7 Suppl):40-4. PubMed ID: 21985979
[TBL] [Abstract][Full Text] [Related]
14. Hyperparathyroidism: primary or secondary disease?
Cordellat IM
Reumatol Clin; 2012; 8(5):287-91. PubMed ID: 22089066
[TBL] [Abstract][Full Text] [Related]
15. [Primary hyperparathyroidism].
Carnevale V; Romagnoli E; Pipino M; Scillitani A; D'Erasmo E; Minisola S; Mazzuoli G
Clin Ter; 2005; 156(5):211-26. PubMed ID: 16382970
[TBL] [Abstract][Full Text] [Related]
16. Mild primary hyperparathyroidism: a literature review.
Applewhite MK; Schneider DF
Oncologist; 2014 Sep; 19(9):919-29. PubMed ID: 25063228
[TBL] [Abstract][Full Text] [Related]
17. Different PTH response to oral peptone load and oral calcium load in patients with normocalcemic primary hyperparathyroidism, primary hyperparathyroidism, and healthy subjects.
Invernizzi M; Carda S; Righini V; Baricich A; Cisari C; Bevilacqua M
Eur J Endocrinol; 2012 Oct; 167(4):491-7. PubMed ID: 22872468
[TBL] [Abstract][Full Text] [Related]
18. Asymptomatic primary hyperparathyroidism.
Silverberg SJ; Walker MD; Bilezikian JP
J Clin Densitom; 2013; 16(1):14-21. PubMed ID: 23374736
[TBL] [Abstract][Full Text] [Related]
19. Primary Hyperparathyroidism.
Bilezikian JP
J Clin Endocrinol Metab; 2018 Nov; 103(11):3993-4004. PubMed ID: 30060226
[TBL] [Abstract][Full Text] [Related]
20. [Medical treatment of primary hyperparathyroidism: role of calcimimetics].
Muñoz Torres M; García Martín A
Endocrinol Nutr; 2009 Apr; 56 Suppl 1():29-34. PubMed ID: 19627758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
